You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pyrotinib

Showing 1 - 25 of 165
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Stage I Trial (Capecitabine,Pyrotinib)

Not yet recruiting
  • Breast Cancer Stage I
  • (no location specified)
May 7, 2023

Breast Cancer Female Trial (Pyrotinib and Trastuzumab)

Not yet recruiting
  • Breast Cancer Female
  • Pyrotinib and Trastuzumab
  • (no location specified)
Sep 11, 2023

Breast Cancer Invasive Trial (pyrotinib)

Not yet recruiting
  • Breast Cancer Invasive
  • pyrotinib
  • (no location specified)
Jun 18, 2023

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2

Recruiting
  • HER2-positive Breast Cancer
  • Early-stage Breast Cancer
  • pyrotinib combined with Capecitabine
  • treatment of physician's choice
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 6, 2023

Breast Cancer Trial in Taizhou (Pyrotinib)

Recruiting
  • Breast Cancer
  • Pyrotinib
  • Taizhou, Zhejiang, China
    Taizhou Hospital
May 26, 2023

Breast Cancer Trial (Pyrotinib, Trastuzumab, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Pyrotinib
  • +2 more
  • (no location specified)
Apr 22, 2023

Breast Cancer Trial in Nanjing (Disitamb Vedotin ,pyrotinib)

Not yet recruiting
  • Breast Cancer
  • Disitamb Vedotin ,pyrotinib
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Aug 18, 2023

HER2-positive Breast Cancer Trial in Nanjing (Pyrotinib)

Recruiting
  • HER2-positive Breast Cancer
  • Pyrotinib
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Apr 26, 2023

Breast Cancer Trial in Yantai (pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

Recruiting
  • Breast Cancer
  • pyrotinib combined with trastuzumab, dalpiciclib and letrozole
  • Yantai, Shandong, China
    Yantai Yuhuangding Hospital
Mar 23, 2023

Breast Cancer Trial in Xi'an (Disitamab Vedotin plus pyrotinib or naratinib)

Not yet recruiting
  • Breast Cancer
  • Disitamab Vedotin plus pyrotinib or naratinib
  • Xi'an, Shaanxi, China
    Xi'an International Medical Center Hospital
Aug 27, 2023

Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

Recruiting
  • HER2-positive Advanced Breast Cancer
  • Inetetamab Combined With Pyrotinib and Vinorelbine
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 3, 2023

Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)

Recruiting
  • Breast Cancer
  • Neoadjuvant
  • pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
  • Wuhan, Hubei, China
  • +1 more
Aug 18, 2023

Breast Cancer Trial in Nanjing (Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate)

Recruiting
  • Breast Cancer
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Apr 10, 2023

HER2-positive Recurrent/Metastatic Breast Cancer Trial (Inetetamab, pyrotinib, chemo)

Not yet recruiting
  • HER2-positive Recurrent/Metastatic Breast Cancer
  • Inetetamab, pyrotinib, chemotherapy
  • (no location specified)
Nov 16, 2022

Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)

Recruiting
  • Breast Cancer With Brain Metastases
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 22, 2023

NSCLC Trial in Beijing (Pyrotinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Pyrotinib
  • Beijing, Beijing, China
    Peking Union Medical College
Feb 20, 2023

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line

Recruiting
  • Breast Neoplasms
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Mar 16, 2023

Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic

Completed
  • Breast Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 20, 2023

    Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

    Not yet recruiting
    • Breast Cancer Invasive
    • +3 more
    • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
    • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Nov 17, 2023

    Breast Cancer, Brain Metastases, HER2-positive Breast Cancer Trial in Shanghai (Pyrotinib Plus Capecitabine combined with brain

    Active, not recruiting
    • Breast Cancer
    • +2 more
    • Pyrotinib Plus Capecitabine combined with brain radiotherapy
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Jan 14, 2023

    Advanced/ Metastatic Her-2 Positive Breast Cancer Trial in Shanghai (GQ1001+pyrotinib, pyrotinib+capecitabine)

    Active, not recruiting
    • Advanced/ Metastatic Her-2 Positive Breast Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Nov 15, 2022

    Breast Tumor Female Trial (Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy)

    Not yet recruiting
    • Breast Neoplasm Female
    • Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy
    • (no location specified)
    Oct 17, 2022

    Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

    Active, not recruiting
    • Breast Cancer
    • Pyrotinib Plus Trastuzumab
    • Pertuzumab Plus Trastuzumab
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 5, 2022

    Healthy Participants Trial (pyrotinib maleate, Loperamide)

    Completed
    • Healthy Participants
    • Changsha, Hunan, China
      Xiangya Hospital Central South University
    Oct 27, 2022

    Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Pyrotinib
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Sep 28, 2022